RU2017122022A - Композиция для введения нуклеиновой кислоты в клетки - Google Patents

Композиция для введения нуклеиновой кислоты в клетки Download PDF

Info

Publication number
RU2017122022A
RU2017122022A RU2017122022A RU2017122022A RU2017122022A RU 2017122022 A RU2017122022 A RU 2017122022A RU 2017122022 A RU2017122022 A RU 2017122022A RU 2017122022 A RU2017122022 A RU 2017122022A RU 2017122022 A RU2017122022 A RU 2017122022A
Authority
RU
Russia
Prior art keywords
copolymer
repeating units
paragraphs
composition
nucleic acid
Prior art date
Application number
RU2017122022A
Other languages
English (en)
Other versions
RU2017122022A3 (ru
RU2715227C2 (ru
Inventor
Кристиан Домен
Кристиан Планк
Карстен Рудольф
Original Assignee
Этрис Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Этрис Гмбх filed Critical Этрис Гмбх
Publication of RU2017122022A publication Critical patent/RU2017122022A/ru
Publication of RU2017122022A3 publication Critical patent/RU2017122022A3/ru
Application granted granted Critical
Publication of RU2715227C2 publication Critical patent/RU2715227C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G73/00—Macromolecular compounds obtained by reactions forming a linkage containing nitrogen with or without oxygen or carbon in the main chain of the macromolecule, not provided for in groups C08G12/00 - C08G71/00
    • C08G73/02—Polyamines
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G73/00—Macromolecular compounds obtained by reactions forming a linkage containing nitrogen with or without oxygen or carbon in the main chain of the macromolecule, not provided for in groups C08G12/00 - C08G71/00
    • C08G73/02—Polyamines
    • C08G73/0206—Polyalkylene(poly)amines
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Polymers & Plastics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)

Claims (26)

1. Статистический полимер, включающий множество повторяющихся звеньев (а), независимо друг от друга выбранных из следующих формул (a1) и (а2):
Figure 00000001
Figure 00000002
, и
множество повторяющихся звеньев (b), независимо друг от друга выбранных из следующих формул (b1) - (b4):
Figure 00000003
Figure 00000004
Figure 00000005
Figure 00000006
где молярное соотношение суммы повторяющихся звеньев (а) и суммы повторяющихся звеньев (b) находится в интервале от 0,7:1,0 до 1,0:0,7, где один или более атомов азота в повторяющихся звеньях (а) и/или (b), содержащихся в сополимере, могут протонироваться с образованием катионного сополимера.
2. Сополимер по п. 1, который является разветвленным или дендритным сополимером, включающим повторяющиеся звенья одного или более типа, выбранных из повторяющихся звеньев (а2), (b2) и (b4).
3. Сополимер по п. 1, который является линейным сополимером, включающим повторяющиеся звенья (a1) и (b1).
4. Сополимер по любому из пп. 1-3, где содержание повторяющихся звеньев (а) и (b) составляет 80 мол. % или более в расчете на все повторяющиеся звенья в сополимере.
5. Сополимер по любому из пп. 1-3, где содержание повторяющихся звеньев (а), выбранных из (a1) и (а2), и повторяющихся звеньев (b), выбранных из (b1) и (b2), составляет 80 мол. % или более в расчете на все повторяющиеся звенья в сополимере.
6. Сополимер по любому из пп. 1-5, где концевые группы сополимера включают группы (с) одного или более типа, независимо выбранные из групп формул (c1)-(c3):
Figure 00000007
Figure 00000008
Figure 00000009
.
7. Сополимер по любому из пп. 1-6, где молярное соотношение повторяющихся звеньев (а) и повторяющихся звеньев (b) находится в интервале 0,8:1,0 до 1,0:0,8.
8. Сополимер по любому из пп. 1-7, который получают при полимеризации смеси мономеров, включающей азиридин, азетидин и необязательно пирролидин.
9. Композиция, включающая нуклеиновую кислоту и сополимер по любому из пп. 1-8.
10. Композиция по п. 9, где нуклеиновой кислотой является мРНК.
11. Композиция п. 9 или 10, где сополимер представляет собой катионный сополимер и где катионный сополимер образует комплекс с нуклеиновой кислотой.
12. Фармацевтическая композиция, включающая композицию по любому из пп. 9-11 и необязательно дополнительный фармацевтически приемлемый носитель и/или разбавитель.
13. Применение сополимера по любому из пп. 1-8 или композиции или фармацевтической композиции по любому из пп. 9-12 для доставки нуклеиновой кислоты в клетку.
14. Способ доставки нуклеиновой кислоты в клетку-мишень иди ткань-мишень, включающий стадию приведения в контакт композиции или фармацевтической композиции по любому из пп. 9-12 с клеткой-мишенью или тканью-мишенью.
15. Способ получения сополимера по любому из пп. 1-7, включающий стадию полимеризации смеси мономеров, включающей азиридин, азетидин и необязательно пирролидин.
RU2017122022A 2014-12-19 2015-12-18 Композиция для введения нуклеиновой кислоты в клетки RU2715227C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14199439.2 2014-12-19
EP14199439.2A EP3034539A1 (en) 2014-12-19 2014-12-19 Compositions for introducing nucleic acid into cells
PCT/EP2015/080669 WO2016097377A1 (en) 2014-12-19 2015-12-18 Compositions for introducing nucleic acid into cells

Publications (3)

Publication Number Publication Date
RU2017122022A true RU2017122022A (ru) 2018-12-24
RU2017122022A3 RU2017122022A3 (ru) 2019-05-22
RU2715227C2 RU2715227C2 (ru) 2020-02-26

Family

ID=52292658

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2017122022A RU2715227C2 (ru) 2014-12-19 2015-12-18 Композиция для введения нуклеиновой кислоты в клетки

Country Status (12)

Country Link
US (1) US11020487B2 (ru)
EP (2) EP3034539A1 (ru)
JP (1) JP6745272B2 (ru)
KR (1) KR102142180B1 (ru)
CN (1) CN107001627B (ru)
AU (1) AU2015366220B2 (ru)
BR (1) BR112017012482B1 (ru)
CA (1) CA2971284C (ru)
DK (1) DK3242903T3 (ru)
ES (1) ES2887404T3 (ru)
RU (1) RU2715227C2 (ru)
WO (1) WO2016097377A1 (ru)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3034539A1 (en) 2014-12-19 2016-06-22 Ethris GmbH Compositions for introducing nucleic acid into cells
DK3317411T3 (da) 2015-06-30 2021-03-15 Ethris Gmbh Atp-bindingskassettefamilie som koder polyribonukleotider og formuleringer deraf
WO2018010815A1 (en) 2016-07-15 2018-01-18 Biontech Rna Pharmaceuticals Gmbh Formulation for administration of rna
CN111601605A (zh) * 2018-01-11 2020-08-28 生物技术Rna制药有限公司 用于施用rna的制剂
US20210137846A1 (en) 2018-04-25 2021-05-13 Ethris Gmbh Cryoprotective agents for particulate formulations
JP2023506293A (ja) * 2019-12-17 2023-02-15 ウニヴェルズィテート ゲント ポリプロピレンイミンを含む非ウイルスベクター
CN111249476B (zh) * 2020-02-19 2023-09-26 深圳厚存纳米药业有限公司 泊洛沙姆和/或泊洛沙胺与脂质组合中性复合物纳米粒
IL305353A (en) 2021-02-26 2023-10-01 Ethris Gmbh Spray formulations for the administration of acid bases
WO2023049814A2 (en) * 2021-09-22 2023-03-30 Sirnaomics, Inc. Nanoparticle pharmaceutical compositions with reduced nanoparticle size and improved polydispersity index
CN116549626A (zh) * 2022-01-27 2023-08-08 深圳瑞吉生物科技有限公司 一种载核酸脂质纳米颗粒冻干制剂及其制备方法与应用
EP4327829A1 (en) 2022-08-26 2024-02-28 Ethris GmbH Stabilization of lipid or lipidoid nanoparticle suspensions
WO2024042236A1 (en) 2022-08-26 2024-02-29 Ethris Gmbh Stable lipid or lipidoid nanoparticle suspensions
CN116478410B (zh) * 2023-06-20 2023-09-12 觅投克(北京)生物医学技术有限公司 一种菊糖修饰的聚乙烯亚胺衍生物及其制备方法和应用

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4711955A (en) 1981-04-17 1987-12-08 Yale University Modified nucleotides and methods of preparing and using same
JPS5821590A (ja) 1981-07-31 1983-02-08 株式会社東芝 制御棒駆動水圧装置
JPS58215490A (ja) * 1982-06-08 1983-12-14 Nippon Shokubai Kagaku Kogyo Co Ltd 石炭−水スラリ−用分散剤
CA1223831A (en) 1982-06-23 1987-07-07 Dean Engelhardt Modified nucleotides, methods of preparing and utilizing and compositions containing the same
US5792608A (en) 1991-12-12 1998-08-11 Gilead Sciences, Inc. Nuclease stable and binding competent oligomers and methods for their use
US5525711A (en) 1994-05-18 1996-06-11 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Pteridine nucleotide analogs as fluorescent DNA probes
FR2722506B1 (fr) * 1994-07-13 1996-08-14 Rhone Poulenc Rorer Sa Composition contenant des acides nucleiques, preparation et utilisations
US5656611A (en) * 1994-11-18 1997-08-12 Supratek Pharma Inc. Polynucleotide compositions
DE19527102A1 (de) * 1995-07-25 1997-01-30 Bayer Ag Neue Polyamine und ihre Verwendung in Lacken und Beschichtungen
US6017700A (en) 1995-08-04 2000-01-25 Bayer Corporation Cationic oligonucleotides, and related methods of synthesis and use
FR2739292B1 (fr) 1995-09-28 1997-10-31 Rhone Poulenc Rorer Sa Composition pharmaceutique utile pour la transfection d'acides nucleiques et ses utilisations
EP1003527A4 (en) * 1997-08-01 2003-07-16 Supratek Pharma Inc POLYNUCLEOTIDE COMPOSITIONS
US8137695B2 (en) * 2006-08-18 2012-03-20 Arrowhead Madison Inc. Polyconjugates for in vivo delivery of polynucleotides
WO2001000708A1 (de) 1999-06-25 2001-01-04 Christian Plank Kombinationen zur einführung von nucleinsäuren in zellen
DE19933024C2 (de) 1999-07-15 2003-03-13 Medinnova Ges Med Innovationen Kationische Blockcopolymere
EP1297169B1 (en) 2000-06-26 2012-08-08 Ethris Gmbh Method for transfecting cells using a magnetic field
US20030215395A1 (en) * 2002-05-14 2003-11-20 Lei Yu Controllably degradable polymeric biomolecule or drug carrier and method of synthesizing said carrier
US20070269891A9 (en) 2003-01-13 2007-11-22 Yasunobu Tanaka Solid surface with immobilized degradable cationic polymer for transfecting eukaryotic cells
JP4535229B2 (ja) 2003-05-08 2010-09-01 国立大学法人 東京大学 ポリエチレングリコール−ポリカチオンブロック共重合体
JP5061349B2 (ja) 2005-02-10 2012-10-31 国立大学法人 東京大学 ポリカチオン荷電性ポリマー及び核酸のキャリヤーとしての使用
CN101346468B (zh) 2005-06-15 2016-03-30 麻省理工学院 含胺脂质和其用途
TR201909609T4 (tr) 2005-08-23 2019-07-22 Univ Pennsylvania Modifiye edilmiş nükleosidleri içeren rna ve kullanım yöntemleri.
WO2007069092A2 (en) 2005-12-15 2007-06-21 Centre National De La Recherche Scientifique (Cnrs) Cationic oligonucleotides, automated methods for preparing same and their uses
US7700541B2 (en) * 2006-04-06 2010-04-20 Nitto Denko Corporation Biodegradable cationic polymers
GB0613753D0 (en) * 2006-07-11 2006-08-23 Norwegian Radium Hospital Res Method
US20090042825A1 (en) * 2007-08-06 2009-02-12 Majed Matar Composition, method of preparation & application of concentrated formulations of condensed nucleic acids with a cationic lipopolymer
US20100004315A1 (en) * 2008-03-14 2010-01-07 Gregory Slobodkin Biodegradable Cross-Linked Branched Poly(Alkylene Imines)
WO2010053572A2 (en) 2008-11-07 2010-05-14 Massachusetts Institute Of Technology Aminoalcohol lipidoids and uses thereof
US20110263025A1 (en) 2008-12-02 2011-10-27 University Of Utah Research Foundation Biodegradable polydisulfide amines for gene delivery
KR20120097484A (ko) 2009-07-31 2012-09-04 에트리스 게엠베하 단백질 발현을 위한 비변형된 뉴클레오티드 및 변형된 뉴클레오티드의 조합을 가진 ｒｎａ
WO2011154331A1 (en) 2010-06-10 2011-12-15 F. Hoffmann-La Roche Ag Polymers for delivery of nucleic acids
AU2012318752B2 (en) 2011-10-03 2017-08-31 Modernatx, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
WO2014025795A1 (en) 2012-08-07 2014-02-13 Northeastern University Compositions for the delivery of rna and drugs into cells
US10258698B2 (en) 2013-03-14 2019-04-16 Modernatx, Inc. Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
EP3034539A1 (en) 2014-12-19 2016-06-22 Ethris GmbH Compositions for introducing nucleic acid into cells

Also Published As

Publication number Publication date
US20180236090A1 (en) 2018-08-23
KR102142180B1 (ko) 2020-08-07
RU2017122022A3 (ru) 2019-05-22
KR20170097124A (ko) 2017-08-25
BR112017012482A2 (pt) 2018-02-27
DK3242903T3 (da) 2021-09-27
CA2971284C (en) 2023-01-10
CN107001627A (zh) 2017-08-01
EP3034539A1 (en) 2016-06-22
EP3242903B1 (en) 2021-07-28
ES2887404T3 (es) 2021-12-22
US11020487B2 (en) 2021-06-01
AU2015366220B2 (en) 2019-09-19
JP2018502956A (ja) 2018-02-01
WO2016097377A1 (en) 2016-06-23
AU2015366220A1 (en) 2017-06-01
EP3242903A1 (en) 2017-11-15
CA2971284A1 (en) 2016-06-23
BR112017012482B1 (pt) 2021-10-19
CN107001627B (zh) 2020-01-14
JP6745272B2 (ja) 2020-08-26
RU2715227C2 (ru) 2020-02-26

Similar Documents

Publication Publication Date Title
RU2017122022A (ru) Композиция для введения нуклеиновой кислоты в клетки
JP2018502956A5 (ru)
EA201400860A1 (ru) Полимер, способ и композиция
EP3549963A3 (en) High molecular weight zwitterion-containing polymers
JP2017519098A5 (ru)
MX2013012934A (es) Nanoparticulas polimericas para el suministro de farmacos.
RU2013114406A (ru) Устойчивая к разрушению лекарственная форма, которая содержит анионный полимер
RU2015101105A (ru) Способ получения композиции на основе гиалуроновой кислоты
AR050190A1 (es) Composiciones para el cuidado oral con polimeros formadores de peliculas
WO2012094574A3 (en) Stabilized polyribonucleotide nanoparticles
EP3418386A3 (en) Compositions and methods for inhibiting gene expression of hepatitis b virus
CU23556A1 (es) Estructura polimérica semejante a dendrímero para la obtención de conjugados de interés farmacéutico
EA201390697A1 (ru) Конъюгаты компонента il-2 и полимера
EA201000747A1 (ru) Система и способ трансдермальной доставки и способ получения системы трансдермальной доставки
BR112014008874A2 (pt) composição de copolímero híbrido de dendrito
BR112015004803A2 (pt) método para preparação livre de solvente de um polímero de ácido (met)acrílico em solução, solução aquosa de polímeros de ácido (met)acrílico, e uso da mesma
CN103834180B (zh) 一种用聚己内酯与聚丙二醇对聚肽膜柔顺性进行改进的方法
WO2013148614A3 (en) Water resistant polymers for personal care
JP2013185119A5 (ru)
EA201691318A1 (ru) Блок-сополимер и клеевая композиция
MY159678A (en) Bimodal neodymium-catalyzed polybutadiene
RU2014145246A (ru) Способ получения амфифильных блок-сополимеров N, N-диметиламиноэтилметакрилата для доставки нуклеиновых кислот в живые клетки
BR112012015184A2 (pt) "processo para preparar um éster cíclico, copolímero, micropartícula,e, micela de polímero"
MX2022003939A (es) Composicion farmaceutica de estabilidad mejorada.
WO2012103208A3 (en) Compositions of glycidyl methacrylate copolymer suitable as chain extender for poly(lactic acid)